SwRI RECEIVES $9.9 MILLION TO DEVELOP NERVE AGENT ANTIDOTE
Principal Investigator(s)
Dr. Jonathan Bohmann
Collaborating Institutions
University of Pittsburgh
Defense Threat Reduction Agency
Medical CBRN Defense Consortium
Funded by
Medical CBRN Defense Consortium
Research Start Date
Status
Active
Southwest Research Institute has received funding from the Medical CBRN Defense Consortium (MCDC) administered by Advanced Technology International to develop a nerve agent antidote for emergency use on the battlefield or to protect public health.
The use of nerve agents continues to be a significant threat to both military and civilian populations. This prototype medication could serve as a countermeasure against a nerve agent attack. SwRI will lead the development of the antidote under the $9.9 million, five-year program, and will collaborate with University of Pittsburgh on the synthesis and compound design, through the support of the Defense Threat Reduction Agency (DTRA).